|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The AUROCs of TE using M and XL probes, SWE, APRI, and FIB-4 were 0.771, 0.761, 0.700, 0.698, and 0.697 respectively, for significant fibrosis; 0.974, 0.973, 0.929, 0.738, and 0.859, respectively, for advanced fibrosis; and 0.954, 0.949, 0.962, 0.765, and 0.962, respectively, for cirrhosis.
|
31799740 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
VCTE demonstrated excellent diagnostic accuracy for the detection of cirrhosis with an AUROC of 0.90 compared with APRI (0.83), FIB-4 (0.88), AAR (0.73) and RPR (0.85).
|
31742822 |
2020 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A larger reduction was observed in persons with more advanced fibrosis/cirrhosis (absolute difference 2.9 for FIB-4<1.25; 5.7 for FIB-4 1.26-3.25; 9.8 for FIB-4>3.25).
|
30977808 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fibrosis score 4 (FIB-4) has been identified as a biochemical surrogate for histological fibrogenesis and fibrosis in cirrhosis.
|
31167732 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The risk of HCC was the highest in patients who had persistently high FIB-4/APRI and both with and without cirrhosis.
|
31222774 |
2020 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The areas under the receiver operating characteristic curves (AUCs) of the LFI for diagnosing significant, advanced LF and liver cirrhosis were significantly higher than those of the APRI and FIB-4, and the LFI had better sensitivity and specificity.
|
31640590 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this pilot study, we assessed serum microRNA (miRNA) expression to distinguish cirrhosis and HCC, alone and in combination with the aminotransferase-to-platelet ratio (APRI), Fibrosis 4 (FIB-4), and alpha-fetoprotein (AFP).
|
30781550 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LPR and IGPR were associated independently with liver fibrosis stage in treatment-naive AIH, and were superior to APRI and FIB-4 in detecting cirrhosis.
|
31107735 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performances of FIB-4 and APRI for the detection of significant fibrosis and cirrhosis proved to be unsatisfactory, with very high false negative and false positive rates among both cohorts.
|
30519966 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum GP73 is an important biomarker in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection, but the value is limited for diagnosing advanced fibrosis and cirrhosis in comparison with APRI and FIB-4.
|
31636735 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The two laboratory indices APRI and FIB-4 index could predict advanced (F3-4) liver fibrosis and cirrhosis (F4), with the area under the receiver operating characteristic curve (AUROC) > 0.8 and accuracy >70%.
|
31831303 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AUCs of ECV<sub>liver</sub> were larger than both APRI and FIB-4 in fibrosis staging, with significant differences in the diagnosis of advanced fibrosis (≥F3) and cirrhosis (F4) (P = 0.0024 to 0.0049).
|
30849483 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic performances of MRE, 2D-SWE, FIB-4, and APRI for assessing significant fibrosis (≥ F2) and cirrhosis (F4) were evaluated with liver histology as the reference standard, using receiver operating characteristic analyses.
|
31333316 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To diagnose liver cirrhosis, AUROCs were higher; 0.82 (0.80-0.83) for FIB-4 and 0.78 (0.76-0.79) for APRI, p < 0.001.
|
31702417 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High baseline FIB-4 index (per 1 point increase) in the treated groups was associated with a higher risk of developing liver cirrhosis (P = 0.001) and HCC (P = 0.038) in univariable analysis.
|
30151861 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the patients who developed HCC, non-SVR patients had significantly higher total bilirubin, higher FIB-4, lower pre-treatment platelet count, higher pre-treatment AFP levels and higher proportion of cirrhosis than SVR patients before occurrence of HCC.
|
30527565 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with rs675520 AG/GG genotypes had decreased odds of having cirrhosis (F4) and advanced fibrosis (FIB-4 ≥ 3.25 and APRI≥1.5) [adjusted Odd Ratio (aOR) = 0.30 (p = 0.025), aOR = 0.20 (p = 0.014), and aOR = 0.34 (p = 0.017), respectively] and lower levels of FIB-4 and APRI [adjusted arithmetic mean ratio (aAMR) = 0.76 (p = 0.003) and aAMR = 0.72 (p = 0.006), respectively].
|
30336268 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the fibrosis index (FIB-4) has been demonstrated to be closely associated with liver fibrosis and cirrhosis.
|
31066014 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fibrosis-4 (FIB-4) index was useful to predict overall survival and the incidence of hepatocellular carcinoma and liver cirrhosis (LC)-related complications but not extrahepatic malignancies.
|
30144360 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
If HCC incidence increases with age, surveillance becomes more cost effective but remains below willingness-to-pay thresholds only for patients with cirrhosis or with pretreatment aspartate aminotransferase to platelet ratio index greater than 2.0 or FIB-4 measurements greater than 3.25.
|
30580095 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For cirrhosis, the area under receiver operating characteristic curves (AUROCs) were 0.841 for HeBCI, 0.708 for FIB-4 and 0.623 for APRI in the model set, and 0.779, 0.690, 0.595 in the validation set.
|
30076017 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas under receiver operating characteristic curves of LSM, APRI, and FIB-4 were 0.78, 0.81, and 0.87 for post-SVR advanced fibrosis (≥ F4) and 0.86, 0.86, and 0.85 for post-SVR cirrhosis (≥ F5), respectively.
|
31654313 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ARFI elastography is a reliable method for non-invasive staging of liver fibrosis in CHC patients when compared to TE with a good diagnostic performance comparable to FIB-4 and APRI scores for the prediction of significant fibrosis and cirrhosis.
|
31028432 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients without cirrhosis before treatment (n = 38,351) had a low risk of HCC, except for those with pre-SVR FIB-4 scores ≥3.25 (HCC risk 1.22%/year) and post-SVR FIB-4 scores ≥3.25 (HCC risk 2.39%/year); risk remained high for many years after SVR.
|
31356807 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Application of conventional cutoffs for FIB-4 in the derivation dataset yielded unclassifiable results in 686 (23%) individuals, and 139 (41%) of the 340 patients with cirrhosis were misclassified as having no cirrhosis.
|
30975477 |
2019 |